Shanghai Hengrui Pharmaceutical Co., Ltd.

Jiangsu Hengrui Medicine Company Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Jiangsu Hansoh Pharmaceuticals Co., Ltd.

Jinagsu Hengrui Medicine Co., Ltd

Fanglong Yang

Feng He

Weikang Tao

Peng Cho Tang

Yang Wayne Wang

Jingjing Yan

Guangyuan Shen

Ling L Zhang

Jiang Fan

Mingxun He

Dongliang Guan

Shanghai Yu

Liangliang Zheng

Xiqian Zhang

Tao Yang

Qing Dong

Lei Chen

Piaoyang Sun

Takuya Matsumoto

Wei Zhang

Gang Chen

Xiaodong Li

Xing Fan

Fuqiang Zhao

Xiao Wu

Ling Zhang

Zhigang Lin

Weimin Wang

Jindong Liang

Hu Feng

Jianghong Fu

Chunfei Wang

Zhichao Xie

Lingxiang Chen

Lianshan Zhang

Qiyue Hu

Hejun Lu

Yali Wang

Jijun Yuan

Yang Wang

Limin Zhang

Hejun Lü

Wangyang Tu

Jianhong Fu

Ang Li

Jihui Han

Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and/or prevention of diabetes.

Fused imidazole derivative, preparation method therefor, and medical use thereof

The present disclosure relates to a tricyclic tetrahydroisoquinoline derivative, a preparation method therefor and an application thereof in medicine. In particular, the present disclosure relates to a tricyclic tetrahydroisoquinoline derivative represented by general formula (I), a preparation method therefor and a pharmaceutical composition comprising said derivative, a use thereof as an estrogen receptor modulator, and a use thereof in preparing a drug for treating estrogen receptor-mediated or dependent diseases or disorders. The substituents in general formula (I) are the same as those defined in the description.

Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine

An indazole derivative, a preparation method therefor, and a pharmaceutical application thereof. In particular, the present invention relates to an indazole derivative represented by general formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, and a use of the derivative as an estrogen receptor modulator in the prevention and/or treatment of an estrogen receptor mediated or dependent disease or condition, the disease being particularly preferably breast cancer. The definition of each substituent in the general formula (I) is the same as that in the description.

Indazole derivative, preparation method therefor, and pharmaceutical application thereof

The present invention relates to an oxopicolinamide derivative, a preparation method therefor and the pharmaceutical use thereof. In particular, the present invention relates to an oxopicolinamide derivative as shown in the general formula (AI), a preparation method therefor and a pharmaceutical composition comprising the derivative, and to the use thereof as a therapeutic agent, in particular as an inhibitor of blood coagulation factor XIa (Factor XIa, FXIa for short) and the use thereof in the preparation of a drug for treating diseases such as thromboembolism, wherein the definition of each substituent in the general formula (AI) is the same as defined in the description. 

Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof

The present invention relates to a five-membered heteroaryl ring bridged ring derivative, a preparation method therefor and the medical use thereof. In particular, the present invention relates to a new five-membered heteroaryl ring bridged ring derivative as shown in formula (I), a preparation method therefor and a pharmaceutical composition comprising the derivative, and the use thereof as a therapeutic agent, in particular as a TGF-&#x3b2; inhibitor, and the use in the preparation of a drug for treating, preventing or reducing cancers mediated by the over-expression of TGF-&#x3b2;, wherein the definition of each substituent in the general formula (I) is the same as defined in the description. 

Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof

The present invention relates to a 3,4-bipyridyl pyrazole derivative, and a preparation method therefor and a medical application thereof. Specifically, the present invention relates to a new 3,4-bipyridyl pyrazole derivative as shown in formula (I), a preparation method for the derivative, a pharmaceutical composition containing the derivative, a use of the derivative as a therapeutic agent, in particular as a TGF-&#x3b2; inhibitor, and a use of the derivative in the preparation of a drug which treats, prevents or reduces cancer mediated by TGF-&#x3b2; overexpression. The substituents in formula (I) have the same definitions as in the description. 

3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof

Ligand-cytotoxic drug conjugates, pharmaceutical compositions, preparation methods, and pharmaceutical uses thereof are provided. More specifically, a ligand-cytotoxic drug conjugate of general formula Pc-(X-Y-D)is provided. The ligand-cytotoxic drug conjugate can be used to treat cancer via receptor modulation.

Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof

The present invention relates to a benzopiperidine derivative, a preparation method thereof and a medical use thereof. In particular, the present invention relates to a benzopiperidine derivative as shown by general formula (I), a preparation method thereof and a pharmaceutical composition containing the derivative, as well as a use thereof as an estrogen receptor modulator in the prevention and/or treatment of estrogen receptor-mediated or dependent diseases or conditions. Preferably, the disease is breast cancer. The substituents in the general formula (I) are the same as those defined in the description. 

Benzopiperidine derivative, preparation method thereof and medical use thereof

The present invention relates to a piperidine derivative and the preparation method and a pharmaceutical use thereof. In particular, the present invention relates to the piperidine derivative as shown by general formula (I) and the preparation method thereof and a pharmaceutical composition containing the same, and the use thereof as an estrogen receptor modulator in the treatment of estrogen receptor mediated or dependent diseases or conditions, the diseases preferably being breast cancer. In the abstract, the definition of each substituent of the general formula (I) is the same as that in the description. 

Piperidine derivative and preparation method and pharmaceutical use thereof

Disclosed in the present invention are polycyclic derivatives as represented by general formula (I), the preparation method thereof, pharmaceutical compositions containing the derivatives and uses thereof as therapeutic agents, especially the GPR40 agonist and in preparation of drugs for treating diseases such as diabetes and metabolic disorders, etc., wherein each substituent in the general formula (I) has the same definition as in the description. 

Polycyclic derivatives, preparation process and pharmaceutical use thereof

C-aryl glucoside derivatives, preparation processes and pharmaceutical uses thereof are disclosed. In particular, C-aryl glucoside derivatives represented by formula (I), with each substituent defined in the application, pharmaceutically acceptable salts or stereoisomers thereof, their preparation methods, and pharmaceutical compositions containing the derivatives as well as their uses as therapeutic agents, particularly as sodium-dependent glucose cotransporter (SGLT)-1 inhibitors, are disclosed. 

C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof

Growing community of inventors

Shanghai, China

Fanglong Yang